Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression (Q43975777)

28 November 2017

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression (English)

1 reference

28 November 2017

Carolyn Bolden-Watson

object named as

Carolyn Bolden-Watson

5

0 references

author name string

Karen L Weihs

1

1 reference

28 November 2017

Trisha L Houser

2

1 reference

28 November 2017

Sharyn R Batey

3

1 reference

28 November 2017

John A Ascher

4

1 reference

28 November 2017

Rafe M J Donahue

6

1 reference

28 November 2017

Alan Metz

7

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

28 November 2017

Biological Psychiatry

1 reference

28 November 2017

51

1 reference

28 November 2017

753-761

1 reference

28 November 2017

9

1 reference

Body weight gain induced by antipsychotic drugs: mechanisms and management

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Prescription medications: a modifiable contributor to obesity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Sertraline in the prevention of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Drugs that cause weight gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Three-year outcomes for maintenance therapies in recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Acute and Long-Term Bupropion Therapy: Response and Side Effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

The assessment of anxiety states by rating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Development of a Rating Scale for Primary Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Long-term nature of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Recognition and management of depression in general practice: consensus statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Continuation drug therapy for major depressive episodes: how long should it be maintained?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Safety profile of sustained-release bupropion in depression: results of three clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(01)01317-8

1 reference

28 November 2017

1 reference